Eco Animal Health Group plc (AIM: EAH), a UK-headquartered global animal health company, has submitted a Marketing Authorisation Application to the European Medicines Agency for ECOVAXXIN® MG, its live poultry vaccine targeting Mycoplasma gallisepticum. The submission marks the second EMA application from ECO's proprietary R&D pipeline, following the EU commercial launch of sister vaccine ECOVAXXIN® MS in July 2026. If approved, ECOVAXXIN® MG would broaden the company's poultry vaccine portfolio and complement its market-leading antibiotic Aivlosin®, which is distributed across more than 70 markets worldwide.

Key Points

  • Eco Animal Health Group plc (AIM: EAH) is a leading global animal health company employing over 200 people worldwide
  • EAH has submitted a Marketing Authorisation Application to the EMA for ECOVAXXIN® MG, a live poultry vaccine targeting Mycoplasma gallisepticum
  • ECOVAXXIN® MS, the first vaccine from ECO's pipeline targeting Mycoplasma synoviae, was commercially launched in the EU in July 2026; ECOVAXXIN® MG received a favourable USDA safety assessment in March 2026
  • Investors will be watching the progress of the EMA review process and parallel US marketing authorisation work

ECOVAXXIN® MG Targets Chronic Respiratory Disease Causing Major Poultry Industry Losses

Mycoplasma gallisepticum is a bacterial pathogen responsible for chronic respiratory disease in chickens, which the announcement states causes decreased egg production and major economic losses in the poultry sector. ECOVAXXIN® MG uses a live, naturally attenuated isolate of the bacteria, which ECO states has been shown to be safe for young chicks. The disease burden associated with Mycoplasma gallisepticum gives the vaccine commercial relevance across major poultry-producing markets, and EMA approval would position ECO to address two of the most economically significant Mycoplasma infections in poultry through its vaccine portfolio.

Second EMA Dossier Submitted as ECOVAXXIN® MS EU Launch Provides Commercial Blueprint

The EMA submission for ECOVAXXIN® MG follows ECO's EU launch of ECOVAXXIN® MS in July 2026, which targeted the related Mycoplasma synoviae infection and represented the first commercial product from ECO's self-funded R&D pipeline. Chief Executive Officer David Hallas stated in the announcement that the submission "reflects the hard work and commitment of our R&D and regulatory teams" and that the regulatory plan "remains in-line with expectations." The company said it looks forward to advancing through the EMA review process towards a planned launch, while continuing parallel work towards US marketing authorisation.

USDA Favourable Safety Assessment in March 2026 Advances US Authorisation Pathway for ECOVAXXIN® MG

Ahead of the EMA submission, ECOVAXXIN® MG received a favourable safety assessment from the United States Department of Agriculture in March 2026, which the company described as an important step towards achieving US marketing authorisation. This dual-market regulatory strategy—targeting both the EU through the EMA and the US through the USDA—mirrors ECO's broader commercial ambition for its vaccine pipeline and supplements the established global distribution network already supporting Aivlosin®, its market-leading antibiotic for respiratory and intestinal diseases in pigs and poultry.

Pipeline Expansion Sits Alongside Aivlosin®, ECO's Antibiotic Distributed to Over 70 Markets

ECO Animal Health's existing commercial platform is anchored by Aivlosin®, distributed to over 70 markets worldwide, providing an established infrastructure through which new pipeline products could be commercialised upon approval. If ECOVAXXIN® MG secures EMA authorisation, it would extend ECO's poultry-focused product range and reinforce the company's stated strategic focus on prevention and vaccines as a complement to its antibiotic offering. Investors may be watching the EMA review timeline and any updates on the US regulatory pathway as the next material milestones for this programme.